潜在可切除的T1-T2期HPV阴性口咽鳞状细胞癌患者接受根治性放化疗的结局
本研究回顾性分析2014至2021年接受放疗或放化疗的70例早期T分期HPV阴性口咽鳞状细胞癌患者,由四名头颈外科医生盲法评估原发灶经口手术可切除性(TOS),并比较潜在可切除与不可切除患者结局。原发灶TOS有利者3年总生存、疾病特异性生存和无进展生存均优于TOS不利者。
要点
- 70例早期T分期HPV阴性口咽鳞状细胞癌患者中,原发灶TOS有利者占66%。
- 原发灶TOS有利者3年总生存76.9%,TOS不利者37.4%,log-rank检验P=0.01。
- 总体评估TOS有利者3年总生存77.3%,不利者46.2%,log-rank检验P=0.01。
核心结论
- TOS有利的HPV阴性早期T分期口咽鳞状细胞癌患者生存结局优于TOS不利患者。
研究设计与样本
- 回顾性分析2014至2021年接受放疗或放化疗的早期T分期HPV阴性口咽鳞状细胞癌患者70例。
- 治疗前影像由四名头颈外科医生盲法评估原发灶经口手术可切除性,并由一名头颈神经放射科医生评估包膜外侵犯。
- 根据原发灶肿瘤本身以及原发灶联合包膜外侵犯有无进行总体评估,比较手术可切除性相关结局。
- 采用Kaplan-Meier曲线和log-rank检验比较总生存、疾病特异性生存和无进展生存。
主要发现
- 原发灶TOS有利者46/70(66%),基于总体评估TOS有利者41/70(58.6%)。
- 原发灶TOS有利 vs 不利的3年总生存为76.9% vs 37.4%(log-rank检验P=0.01)。
- 原发灶TOS有利 vs 不利的3年疾病特异性生存为78.1% vs 46.2%(log-rank检验P=0.03)。
- 原发灶TOS有利 vs 不利的3年无进展生存为69.9% vs 41.3%(log-rank检验P=0.04)。
- 总体评估TOS有利 vs 不利的3年总生存为77.3% vs 46.2%(log-rank检验P=0.01),疾病特异性生存为78.2% vs 56.5%(P=0.04),无进展生存为72.3% vs 42.1%(P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transoral surgical resectability (TOS) is a prognostic factor for patients with HPV+ T1-2 oropharyngeal squamous cell carcinoma (OPSCC) disease undergoing radiotherapy (RT), but it is unclear whether this holds for HPV-negative (HPV-) patients. We aimed to compare outcomes of potential TOS-candidates vs. non-TOS candidates, among patients who underwent RT/CRT for early T-stage HPV- OPSCC. METHODS: For patients treated with RT/CRT for early T-stage HPV-negative OPSCC between 2014 and 2021, pretreatment imaging was reviewed by four head-and-neck surgeons, masked to clinical outcomes, to assess primary-site suitability for TOS. Extracapsular extension (ECE) was assessed by a head-and-neck neuroradiologist. We compared outcomes based on surgical resectability relating to: (1) the primary site tumor alone, and (2) the primary site plus the absence/presence of ECE (overall assessment). Kaplan-Meier curves for overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS) were compared using the log-rank test. RESULTS: Seventy patients were included in the analysis. The primary site was TOS-favorable in 46/70 (66%). Based on the overall assessment, 41/70 (58.6%) were TOS-favorable. The 3-year OS, DSS and PFS for primary site TOS-favorable versus unfavorable were OS: 76.9% versus 37.4%; DSS: 78.1% versus 46.2%, PFS: 69.9% versus 41.3%, (log-rank test = 0.01, 0.03, 0.04; respectively). Additionally, patients with an overall assessment of TOS favorability demonstrated better survival outcomes compared with TOS-unfavorable patients (OS: 77.3% vs. 46.2%; DSS: 78.2% vs. 56.5%, PFS: 72.3% vs. 42.1%, log-rank test = 0.01, 0.04, 0.01; respectively). CONCLUSION: Patients with TOS-favorable HPV-negative early T-stage OPSCC have superior survival outcomes than TOS-unfavorable patients.
引用
- Laxague F, Fnais N, Son HY, et al. Outcomes for potentially Resectable patients undergoing primary chemoradiation treatment for T1-T2 HPV Negative oropharyngeal squamous cell carcinoma. Head Neck. 2024. PMID: 38779999. doi:10.1002/hed.27802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。